
Skin Cancer & Melanoma
Latest News
Video Series

Latest Videos
Shorts






Podcasts
More News

Experts discussed identifying high-risk cutaneous squamous cell carcinoma and how cemiplimab data from EMPOWER-CSCC-1 and C-POST inform multidisciplinary care.

Catch up on 5 melanoma and skin cancer readouts from ESMO 2026, including NADINA, OptimUM-01, OptimUM-09, C-POST, and KEYNOTE-630.

In STARBOARD, frontline encorafenib, binimetinib, and pembrolizumab improved ORR and PFS vs pembrolizumab alone in BRAF V600E/K-mutant melanoma.

Full INTerpath-001 data at ESMO 2026 detail OS, subgroup, and safety results with intismeran plus pembrolizumab in resected stage IIB to IV melanoma.

Intismeran autogene plus pembrolizumab cut the risk of recurrence or death by 42% vs pembrolizumab alone in resected stage IIB-IV melanoma.

Cosibelimab is now a preferred, category 2A NCCN option for locally advanced CSCC when curative surgery or radiation is not feasible.

Final 5-year IMCgp100-202 data show tebentafusp improved OS vs investigator’s choice in untreated HLA-A*02:01–positive metastatic uveal melanoma.

The FDA approved the first and only photodynamic therapy for the treatment of a skin cancer.

Matteo S. Carlino, MD, PhD, FRACP, discussed V940 plus pembrolizumab data, safety, and administration in resected melanoma.

Final COMBI-I data show a survival advantage with spartalizumab plus dabrafenib/trametinib over dabrafenib/trametinib alone in BRAF V600-mutant melanoma.

Results from the INTERpath-001 trial of V0940 plus pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in resected melanoma.

The FDA approved the PGDx elio tissue complete CDx to identify patients with advanced melanoma with BRAF V600E/K variants eligible for targeted therapy.

The FDA has approved RP1 plus nivolumab for adults with advanced melanoma who progressed on anti–PD-1 therapy.

Researchers have reported the first known case of TIL therapy in a patient with well-controlled HIV and metastatic melanoma.

The FDA's CTGTAC voted 10-3 in favor RP1 plus nivolumab's benefit-risk profile in anti–PD-1–resistant advanced melanoma.

As the FDA's ODAC prepares to weigh in ahead of an August 2, 2026, decision date, take a look at RP1's clinical trial and regulatory journey.

Miguel A. Materin, MD, discussed insights on multidisciplinary care, intra-arterial chemotherapy, and the evolving landscape of uveal melanoma treatments.

Miguel A. Materin, MD, discussed his new leadership role at Northwell Cancer Institute, and why a multidisciplinary approach is critical to managing ocular malignancies.

FDA breakthrough designation and NCCN inclusion elevate Merlin CP-GEP as a tool to refine SLNB decisions in T1b/T2a melanoma, per MERLIN_001 trial data.

In this patient case, a 72-year-old male with primary malignant melanoma of the ascending colon received adjuvant therapy consisting of immunotherapy with PD-1 inhibitors.



























































































